Bevacizumab辅助治疗小梁切除术的临床研究进展  

Recent advances of bevacizumab as an adjunct to trabeculectomy

作　　者：陈娟(综述) 于文贞(审校)[1] Chen Juan;Yu Wenzhen(Department of Ophthalmology,Peking University People ＇s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院眼科,100044

出　　处：《中华实验眼科杂志》2018年第8期649-652,共4页Chinese Journal Of Experimental Ophthalmology

基　　金：国家自然科学基金项目（2101000263）

摘　　要：青光眼是一组以特征性视神经损害和视野缺损为特点的眼病，病理性眼压增高是其主要危险因素，目前的治疗策略主要包括药物控制眼压和手术降低眼压。小梁切除术联合使用抗代谢药物是手术治疗青光眼的常用方法，但由于术后瘢痕形成和并发症多，远期效果尚不能令人满意。已有研究证实，青光眼患者小梁切除术后血管内皮生长因子（VEGF）水平增高，而VEGF在滤过术后瘢痕形成过程中有重要作用。Bevacizumab是人重组单克隆抗体，能够与VEGF各亚型非特异性结合，从而减少滤过泡瘢痕及减轻抗代谢药物的毒性反应。国外多项研究表明，玻璃体腔、前房、结膜下注射bevacizumab和局部点眼均能提高滤过手术成功率。本文就VEGF在小梁切除术后滤过泡瘢痕形成中的作用、bevacizumab辅助治疗小梁切除术治疗机制、给药方式及剂量的研究进展进行综述。Glaucoma is a group of diseases characterized by progressive optic nerve damage and characteristic visual field defect.Increased intraocular pressure is the main risk factor for glaucoma progression.Trabeculectomy combined with adjunctive antimetabolites has been commonly used in glaucoma treatment currently.Several studies have shown that the vascular endothelial growth factor （VEGF） concentration is increased in the eyes after trabeculectomy treatment, which is certainly related to scar formation.As a humanized recombined monoclonal antibody, bevacizumab not only limits the formation of scar, but also eliminates the toxic effects of antimetabolites by unselectively binding with different isoforms of VEGF.Many studies found that intravitreal, subconjunctival, intracameral and topic bevacizumab could improve the success rate of trabeculectomy.In this paper, role of VEGF in the formation of follicular scar after trabeculectomy, together with the treatment mechanism, administration method and dosage of adjuvant bevacizumab therepy to trabeculectomy were reviewed.

关 键 词：青光眼 小梁切除术 血管内皮生成因子 BEVACIZUMAB 

分 类 号：R979.1[医药卫生—药品]